Psyched Wellness Provides Comprehensive Investor Update

Toronto, Ontario--(Newsfile Corp. – April 10, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to announce that its US subsidiary, AME Wellness Inc., working with its advisors, Zerkalo LLC, have completed an initial pilot run of our new dietary supplement in the form of a 4oz shot. The purpose of this pilot run is to beta test the shot with a select target group of consumers and gather feedback on the taste, the effect, and marketing data relating to the product. As part of this process, the Company will stress test its website, 3PL and shipping process to ensure that its fulfilment capabilities are in place in advance of the product launch. 

“We are very excited to share this next phase in the development of our new dietary supplement shot" says, Jeff Stevens, CEO of the Company. "Zerkalo, our partners in the brand development have done an excellent job building this product and we look forward to sharing it in full, when the team is ready to launch.” 

Psyched Wellness will be growing their route-to-market partnerships, throughout the nation. If you are interested in distributing/listing Calm, please reach out to sales@psyched-wellness.com.